Drugs / T601
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04226066 | Nov 2019 → May 2021 | cancer | Tasly Tianjin Biopharmaceutical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | T601 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04226066 ↗ |